Dersimelagon phosphate is under clinical development by Mitsubishi Tanabe Pharma and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dersimelagon phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dersimelagon phosphate overview
MT-7117 is under development for the treatment of erythropoietic protoporphyria and diffuse cutaneous systemic sclerosis. It is a small molecule that administered through the oral route. The drug candidate acts by targeting selective melanocortin 1 receptor (MC1R). It was under development for the treatment of inflammation, autoimmune and dermatological disorders.
Mitsubishi Tanabe Pharma overview
Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.
For a complete picture of Dersimelagon phosphate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
